MedTrace Logo

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

NCT05961202 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-10-09

No results posted yet for this study

Summary

Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine 200mg qd

DRUG

Prednisolone

Prednisolone 20mg qd

Sponsors & Collaborators

  • Wuhan Central Hospital

    collaborator OTHER

  • Taihe Hospital

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2024-09-01
Completion
2025-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961202 on ClinicalTrials.gov